期刊文献+

中医治疗类风湿关节炎的临床疗效分析 被引量:6

Clinical effects analysis of treating rheumatoid arthritis in TCM
下载PDF
导出
摘要 目的:观察四妙消痹(SMXB)汤治疗类风湿关节炎的临床疗效。方法:将180例患者随机分为四妙消痹汤治疗组(90例)和甲氨蝶呤对照组(90例),疗程3个月,评价疗效。结果:治疗组总有效率87.8%,愈显率38.9%,起效时间(5.21±0.4)周,均显著优于对照组(P<0.05)。结论:四妙消痹汤治疗类风湿关节炎起效快、疗效确切,值得推广和应用。 Objective:To observe the clinical effect of treating rheumatoid arthritis in Simiao Xiaobi decoction.Methods:180 cases were randomly divided into Simiao Xiaobi decoction treatment group(90 cases)and methotrexate control group(90 cases),for 3 months as a course,then evaluate its effects.Results:The total effective rate in treatment group was 87.8%,cured in 38.9%,and which working time was(5.21±0.4)weeks,which all better than control group(P〈0.05).Conclusion:Treating rheumatoid arthritis in Simiao Xiaobi decoction had good effects,so it was worth widely using.
作者 张利君
机构地区 长沙仁康医院
出处 《中医临床研究》 2011年第18期28-29,共2页 Clinical Journal Of Chinese Medicine
关键词 类风湿关节炎 四妙消痹汤 疗效 Rheumatoid arthritis Simiao Xiaobi decoction Effects
  • 相关文献

参考文献3

二级参考文献27

  • 1孙晓龙,王宽宇,张丹琦.土茯苓注射液抗炎、镇痛作用的实验研究[J].中国中医药科技,2004,11(4):231-232. 被引量:52
  • 2胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量:86
  • 3侯勇,张奉春,黄烽,吴东海,鲍春德,倪立青,姚晨.Infliximab治疗类风湿关节炎的随机双盲平行多中心临床试验[J].中华风湿病学杂志,2006,10(11):658-663. 被引量:34
  • 4Fransen J,van Riel PL.The disease activity score and the EULAR response criteria[J].Clin Exp Rheumatol,2005,23(5 Suppl 39):S93-S99.
  • 5Shealy DJ,Wooley PH,Emmell E,et al.Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice.Arthritis Res,2002,4:R7.
  • 6Siegel SA,Shealy DJ,Nakada MT,et al.The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.Cytokine,1995,1:15-25.
  • 7D'Haens DR.Infliximab as disease-modifying therapy.Eur'J Gastroenterol Hepatol,2003,15:233-237.
  • 8Maini R,St Clair EW,Breedveld F,et al.Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomised phase Ⅲ trial.Lancet,1999,354:1932-1939.
  • 9Lipsky PE,van der Heijde DMFM,St Clair EW,et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis.N Engl J Med,2000,343:1594-1602.
  • 10Harriman G,Harper LK,Schaible TH.Summary of clinical trials in rheumatoid arthritis using infliximab,an anti-TNF-α treatment.Ann Rheum Dis,1999,58:161-164.

共引文献63

同被引文献37

  • 1金冶,李杰.加味独活寄生汤治疗类风湿关节炎的临床分析[J].现代康复,1999,3(8):1003-1003. 被引量:1
  • 2蒋燕.湿热体质与疾病关系研究[J].北京中医药大学学报,2005,28(4):16-18. 被引量:36
  • 3姜泉,蒋红,曹炜,焦娟.475例类风湿关节炎患者中医临床证候分析[J].中医杂志,2007,48(3):253-255. 被引量:140
  • 4Rooney T, Edwards CK 3^rd, Gogarty M, et al. Synovial tissue rank ligand expression and radiographicprogression in rheumatoid arthritis : observations from a proof of concept randomized clinical trial of cytokineblockade [ J ]. Rheumatol lnt, 2010,30 ( 12 ) : 1571.
  • 5Singh P P, van der Kraan A G, Xu J, et al. Membrane-bound receptor activator of NF-KB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors[ J ]. Biochem Biophys ResCommun,2012,422( 1 ) :48.
  • 6郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:115-119.
  • 7Ospeh C, Neidhart M, Gay RE, et al. Synovial activation in rheumatoid arthritis[J]. Front Biosci, 2004,9 : 2323-2334.
  • 8Kay J,Calabrese L. The role of interleukin-1 in the patho- genesis of rheumatoid d arthritis [J]. Rheumatology (Ox- ford), 2004,43(Suppl 3 ) : 12-19.
  • 9Nishimoto N,Ito A,Ono M,et al. IL-6 inhibits the pro- liferati on of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor [J]. Int Immunol,2000,12(2) : 187-193.
  • 10Choy EH, Panayi GS. Cytokine pathways and joint in flam- mati on in rheumatoid Arthritis [J]. N Engl J Med,2001, 344(12) :907-916.

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部